Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Next-Generation Calcineurin Modulator Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PPP3R2 (Calcineurin BII) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PPP3R2 Full-Length Recombinant Protein. High purity (>95%), Endotoxin <1EU/µg, Sequence Verified. Theoretical MW 19.5 kDa. Apo-form and Ca2+-saturated available. | View PPP3R2 Products |
| Gene Delivery | PPP3R2 Promise-ORF / Lentivirus. Full-length ORF (NM_021130) for stable cell lines, CMV promoter, Puromycin selection. | View PPP3R2 Products |
| Benchmark Ab | Anti-PPP3R2 Rabbit Polyclonal Antibody. Affinity purified, cross-reactivity pre-absorbed vs. PPP3R1, validated for WB/IHC. | View PPP3R2 Products |
| Validator | PPP3R2 siRNA Set (3 unique targets targeting 3'UTR, no homology to PPP3R1). Negative control included. | View PPP3R2 Products |
| Catalytic Partner | PPP3CA (Calcineurin A). Required for heterodimer formation and phosphatase activity assays. Pre-formed PPP3CA-PPP3R2 complex protein available (1:1 stoichiometry verified by SEC-HPLC). | View PPP3CA Products |
| Isoform Comparator | PPP3R1 (Calcineurin B Type I). Ubiquitous isoform for selectivity screening against PPP3R2. | View PPP3R1 Products |
| Downstream Effector | NFATC1 (Nuclear Factor of Activated T-cells). Substrate for functional calcineurin phosphatase assays. | View NFATC1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Calcium-dependent conformational integrity | Apo-form and Ca2+-saturated PPP3R2 available; EF-hand domains sequence-verified; >95% purity by SDS-PAGE. |
| Isoform Selectivity Screening (R2 vs R1) | Human PPP3R2 and PPP3R1 proteins side-by-side; strict mass spec identity confirmation; <0.1% cross-contamination. |
| Heterodimer Assembly (with PPP3CA) | Pre-formed PPP3CA-PPP3R2 Complex Protein available; 1:1 stoichiometry verified by SEC-HPLC. |
| Tissue Specificity Validation | Isoform-specific antibody (epitope mapping against R2-specific C-terminal region). |
| Knockdown Specificity | siRNA targeting unique 3'UTR of PPP3R2 (no homology to PPP3R1) for genetic validation. |
| Lack of Reliable Controls | Sequence Verified recombinant positive control antibodies included. |
| Target Validation False Positives | Validated siRNA included for specificity checks. |
Live PPP3R2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Resistance Research
- ➤ Latest Isoform-Selective Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The calcineurin inhibitor landscape is transitioning from broad immunosuppression toward tissue-specific modulation. PPP3R2 (Calcineurin BII), predominantly expressed in testis and brain, represents a critical differentiation node for next-generation therapeutics. Unlike the ubiquitous PPP3R1 isoform, selective targeting of PPP3R2 offers a mechanistic avenue for male contraception without systemic immunosuppression, as well as neuroprotective strategies that bypass the nephrotoxicity associated with traditional calcineurin inhibitors. Major players are shifting focus from traditional broad-spectrum inhibitors to highly selective Small Molecules and PROTACs. The next wave of R&D is targeting non-hormonal male contraception and neuroprotection where tissue-restricted expression of PPP3R2 enables therapeutic window.
Competitive Modality & Indication Snapshot
| Modality | Representative Approach | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Isoform-Selective Small Molecules | Allosteric disruptors of R2-A interface | Male Contraception, Neuroprotection | Heterodimer disruption assay (Need pre-formed PPP3R2-PPP3CA complex) |
| PROTACs | Targeted protein degradation of PPP3R2 | Targeted Oncology | Ternary complex validation (Need sequence verified proteins) |
| Peptide Inhibitors | Cell-penetrating peptides targeting R2-specific pockets | Targeted Immunosuppression | Competition binding assays (Need high-purity R2 vs R1 proteins) |
| siRNA / Gene Therapy | Testis-specific siRNA delivery | Reversible Contraception | Specificity controls (Need PPP3R2-specific siRNA and R1 cross-reactivity check) |